Kahana L, Ackermann J, Lefor W, Weinstein S, Wright C, DeQuesada A, Alveranga D, Baxter J, Shires D
Department of Internal Medicine, University of South Florida, Tampa.
Transplant Proc. 1990 Aug;22(4):1755-8.
We have shown that OKT3 can be safely administered to a varied group of transplant recipients, including a high percentage of diabetics and older patients. Used as a prophylactic agent, OKT3 was associated with a decreased incidence and delayed onset of acute rejection. Effectiveness may be reduced by shortening the course of treatment and/or lowering the dose of concomitant azathioprine. Use of OKT3 in patients with ATN (thereby avoiding use of CyA) may be a beneficial strategy. Stimulation of significant titers of antimurine antibody has not been a common event in this study.
我们已经证明，OKT3可安全用于各类移植受者，包括高比例的糖尿病患者和老年患者。作为一种预防药物，OKT3与急性排斥反应的发生率降低及发作延迟相关。缩短治疗疗程和/或降低硫唑嘌呤的伴随剂量可能会降低疗效。在急性肾小管坏死患者中使用OKT3（从而避免使用环孢素）可能是一种有益的策略。在本研究中，刺激产生高滴度抗鼠抗体并非常见情况。
